ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Edwards Lifesciences Corporation Investors To Secure Counsel Before Important Deadline In Securities Class Action – EW
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Edwards Lifesciences Corporation Investors To Secure Counsel Before Important Deadline In Securities Class Action – EW . (MENAFN - GlobeNewsWire - Nasdaq) NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) --    WHY:   Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Edwards Lifesciences ...
América - MenaFN
(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024, both dates inclusive (the“Class Period”), of the important December 13, 2024 lead plaintiff deadline.

SO WHAT: If you purchased Edwards securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Edwards class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email ... for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 13, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants provided investors with material information concerning Edwards' expected revenue for the fiscal year 2024, particularly as it related to the growth of Edwards' core product, Transcatheter Aortic Valve Replacement (“TAVR”). Defendants' statements included, among other things, strong commitment to the TAVR platform, confidence in Edwards' ability to capitalize on a subset of untreated patients through scaling of its various patient activation activities, and continued claims of significant demand in allegedly lower-penetrated markets. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Edwards class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email ... for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: , on Twitter: or on Facebook: .

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

...
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108903934/ROSEN-TRUSTED-INVESTOR-COUNSEL-Encourages-Edwards-Lifesciences-Corporation-Investors-To-Secure-Counsel-Before-Important-Deadline-In-Securities-Class-Action-EW
2024-11-19
rss
(MENAFN - GlobeNewsWire - Nasdaq) NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) --    WHY:   Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Edwards Lifesciences ...
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Edwards Lifesciences Corporation Investors To Secure Counsel Before Important Deadline In Securities Class Action – EW